Results 141 to 150 of about 11,352 (187)
Some of the next articles are maybe not open access.
Annual Review of Medicine, 1979
Hairy cell leukemia, or leukemic reticuloendotheliosis, is a chronic leu kemia that has received increased attention in recent years. Much of the current vogue in the recognition of this disease may be due to the employ ment of the term "hairy cell," first used by Schrek & Donnelly (1) to describe the villous cytoplasmic projections of the leukemic ...
R C, Braylan, J S, Burke
+13 more sources
Hairy cell leukemia, or leukemic reticuloendotheliosis, is a chronic leu kemia that has received increased attention in recent years. Much of the current vogue in the recognition of this disease may be due to the employ ment of the term "hairy cell," first used by Schrek & Donnelly (1) to describe the villous cytoplasmic projections of the leukemic ...
R C, Braylan, J S, Burke
+13 more sources
Current Treatment Options in Oncology, 2007
Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease, characterized by splenomegaly and pancitopenia related to this. The lymphocytes present characteristic citoplasmatic projections and are positive for tartrate-resistant acid phosphatase (TRAP).
Riccioni, Rossella +2 more
+8 more sources
Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease, characterized by splenomegaly and pancitopenia related to this. The lymphocytes present characteristic citoplasmatic projections and are positive for tartrate-resistant acid phosphatase (TRAP).
Riccioni, Rossella +2 more
+8 more sources
Critical Reviews in Oncology/Hematology, 1987
Hairy cell leukemia is a chronic lymphoproliferative disorder that has been recognized as a separate clinical pathologic entity for the last 25 years. After a decade of discussions about the origin of the neoplastic cell, it has now been well established that hairy cells represent a certain, rather mature stage of B-cell differentiation.
Jan Jansen, L.T. Yam
openaire +4 more sources
Hairy cell leukemia is a chronic lymphoproliferative disorder that has been recognized as a separate clinical pathologic entity for the last 25 years. After a decade of discussions about the origin of the neoplastic cell, it has now been well established that hairy cells represent a certain, rather mature stage of B-cell differentiation.
Jan Jansen, L.T. Yam
openaire +4 more sources
Current Treatment Options in Oncology, 2001
The standard therapy for hairy cell leukemia (HCL) is with the nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine (CdA), which produce morphologic complete remissions (CRs) in the majority of patients, although residual hairy cells can frequently be detected by molecular or immunologic techniques.
L, Savoie, J B, Johnston
openaire +3 more sources
The standard therapy for hairy cell leukemia (HCL) is with the nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine (CdA), which produce morphologic complete remissions (CRs) in the majority of patients, although residual hairy cells can frequently be detected by molecular or immunologic techniques.
L, Savoie, J B, Johnston
openaire +3 more sources
Current Oncology Reports, 2006
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Current Problems in Cancer, 1984
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +2 more sources
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +2 more sources
Leukemia Research, 1987
A mother and son are reported who both developed hairy cell leukemia. The mother aged 74 presented with pancytopenia and responded well to splenectomy. Four years later her son aged 48 presented with pancytopenia; splenectomy was less effective but he improved after treatment with interferon-alpha. Histological examination of the splenic tissue in both
C G, Begley +5 more
openaire +2 more sources
A mother and son are reported who both developed hairy cell leukemia. The mother aged 74 presented with pancytopenia and responded well to splenectomy. Four years later her son aged 48 presented with pancytopenia; splenectomy was less effective but he improved after treatment with interferon-alpha. Histological examination of the splenic tissue in both
C G, Begley +5 more
openaire +2 more sources
Clinical Lymphoma and Myeloma, 2009
Progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease. With current regimens, the majority of patients achieve a complete remission, and their survival curves are similar to those for appropriate age-matched individuals without the disease.
openaire +2 more sources
Progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease. With current regimens, the majority of patients achieve a complete remission, and their survival curves are similar to those for appropriate age-matched individuals without the disease.
openaire +2 more sources
Acta Haematologica, 1995
A 59-year-old man presented with lymphocytosis with huge splenomegaly. The abnormal lymphocytes had a high nucleoplasm:cytoplasm ratio, a prominent nucleolus and hairy cytoplasmic projections. Immunophenotyping revealed B-cell leukemia with negative reactions to CD5 and CD25. Cytogenetic study showed 46,XY,der(5)t(5;6)(q35;p21), del(7)(p13)/46,idem,add(
P, Dunn, L Y, Shih, Y S, Ho, H F, Tien
openaire +2 more sources
A 59-year-old man presented with lymphocytosis with huge splenomegaly. The abnormal lymphocytes had a high nucleoplasm:cytoplasm ratio, a prominent nucleolus and hairy cytoplasmic projections. Immunophenotyping revealed B-cell leukemia with negative reactions to CD5 and CD25. Cytogenetic study showed 46,XY,der(5)t(5;6)(q35;p21), del(7)(p13)/46,idem,add(
P, Dunn, L Y, Shih, Y S, Ho, H F, Tien
openaire +2 more sources
Leukemia & Lymphoma, 1998
Familial hairy cell leukemia (HCL) occurs rarely, and HCL occurring in association with other hematologic malignancies is even rarer. We describe two cases of familial HCL syndromes: a mother and son with HCL, and a HCL patient whose aunt developed Hodgkin's Disease (HD). This is the first reported familial association of HCL with HD.
D, Makower +3 more
openaire +2 more sources
Familial hairy cell leukemia (HCL) occurs rarely, and HCL occurring in association with other hematologic malignancies is even rarer. We describe two cases of familial HCL syndromes: a mother and son with HCL, and a HCL patient whose aunt developed Hodgkin's Disease (HD). This is the first reported familial association of HCL with HD.
D, Makower +3 more
openaire +2 more sources